# Matthew R. Smith

Source: https://onco.cc/people/matthew-smith/  
OnCo record `matthew-smith` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led ARASENS and SPARTAN, trials that established darolutamide triplet therapy and apalutamide for prostate cancer.

## Summary

Matthew Smith was principal investigator of ARASENS, which showed darolutamide added to androgen deprivation and docetaxel improves survival in metastatic hormone-sensitive prostate cancer, and of SPARTAN, which established apalutamide for non-metastatic castration-resistant disease. He has led landmark studies of bone loss and denosumab in men on hormone therapy.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: prostate; trialist
- Role: Director, Genitourinary Malignancies Program, Massachusetts General Hospital Cancer Center
- Specialisms: Prostate cancer; Androgen receptor inhibitors; Bone health; Non-metastatic castration-resistant disease

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Smith%20MR%5BAuthor%5D%20darolutamide%20OR%20apalutamide

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- technologies: [Androgen deprivation & AR pathway inhibitors](https://onco.cc/technologies/androgen-deprivation/)
- targets: [Androgen receptor](https://onco.cc/targets/androgen-receptor/)
- institutions: [Massachusetts General Hospital Cancer Center](https://onco.cc/institutions/mgh/)
- trials: [ARASENS](https://onco.cc/trials/arasens/)

---
JSON: https://onco.cc/api/v1/entities/matthew-smith.json